Latest / The Well-Built Life / Heart Failure without Strong Pumping: Navigating the Complexities
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:15Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Let's dive right into heart failure
- 0:26Speaker 1: with Preserved Ejection Fraction, or HFPF. Over 3 million Americans
- 0:31Speaker 1: are living with this condition, and most of them are women.
- 0:36Speaker 1: What's interesting about HFPF is that it's often sneaky. It
- 0:40Speaker 1: isn't as clear, cut as other heart conditions. What key
- 0:44Speaker 1: risk factors do we see here?
- 0:45Speaker 2: Absolutely. The risk factors are multifaceted. Older age, hypertension, and
- 0:51Speaker 2: diabetes are big contributors. In fact, 80% of HFPF patients
- 0:56Speaker 2: also suffer from pulmonary hypertension, or PHT. This PHT can
- 1:01Speaker 2: lead to PHFPF, which is super problematic because it can
- 1:05Speaker 2: cause severe breathlessness and fatigue, really impacting their daily lives.
- 1:10Speaker 1: That's a staggering number. The prevalence is particularly high in women, right?
- 1:15Speaker 1: And what are the specific impacts on quality of life
- 1:18Speaker 1: for these folks? Let's talk about the symptoms they experience.
- 1:22Speaker 2: Exactly. Patients often face severe breathlessness and extreme fatigue. finding
- 1:27Speaker 2: even simple tasks like walking to the mailbox a challenge.
- 1:31Speaker 2: The heart is essentially working overtime to pump blood, and
- 1:34Speaker 2: the resulting stiffened and thickened walls of the left ventricle
- 1:37Speaker 2: further reduce blood flow during daily activities. For many, this
- 1:41Speaker 2: condition is a daily struggle.
- 1:43Speaker 1: And to complicate things, the exact mechanisms behind HFPF aren't
- 1:47Speaker 1: fully understood, making it hard to spot it early. To
- 1:51Speaker 1: raise a lot of complexity here, Let's focus on some
- 1:54Speaker 1: new research that's starting to unravel these mysteries. I am
- 1:58Speaker 1: thinking of the study at the University of Wisconsin-Madison and
- 2:02Speaker 1: the Morgridge Institute. They have identified some potentially game-changing mechanisms.
- 2:07Speaker 2: Yes, these researchers are looking at mitochondrial function and RNA
- 2:12Speaker 2: metabolism and transport, as some genes like GAD3 were differentially
- 2:16Speaker 2: expressed in patients with RV dysfunction. That suggests disrupted energy metabolism.
- 2:22Speaker 2: which could be a key player in HFPF. It's fascinating
- 2:26Speaker 2: how these underlying cellular processes could be targeted for future therapies. Right.
- 2:32Speaker 1: The study used long-read RNA sequencing, which is really cutting-edge.
- 2:37Speaker 1: They are evaluating heart tissue biopsies from these patients to
- 2:41Speaker 1: understand the molecular and cellular differences. This could pave the
- 2:45Speaker 1: way for more tailored treatments, finally moving beyond the one-size-fits-all approach.
- 2:51Speaker 2: Exactly. And it's not just about finding the mechanisms. The
- 2:54Speaker 2: research also highlights the importance of using comprehensive cardiac assessments
- 2:59Speaker 2: and invasive testing. For example, 19 patients out of 48
- 3:03Speaker 2: in their study had right ventricular dysfunction, and these showed
- 3:07Speaker 2: significantly higher mortality and hospitalization rates.
- 3:10Speaker 1: That's wild. So, these new methods could help clinicians better
- 3:15Speaker 1: identify those at high risk. What about the treatment trials?
- 3:20Speaker 1: Any promising results from recent clinical research?
- 3:23Speaker 2: Unfortunately, some trials have had mixed results. For instance, a
- 3:28Speaker 2: clinical trial of oral levosamendin for PHF-PIF was unsuccessful. This
- 3:34Speaker 2: indicates the need for more targeted approaches. However, the study
- 3:38Speaker 2: did uncover some potential targets, like increased turbulence and flooding
- 3:43Speaker 2: in the lungs when more flow is sent through the
- 3:45Speaker 2: pulmonary arteries.
- 3:46Speaker 1: That's a tough pill to swallow, but it's a step
- 3:49Speaker 1: in the right direction. The more we understand about the
- 3:52Speaker 1: intricate mechanisms, the closer we get to finding effective treatments.
- 3:56Speaker 1: And all of this is thanks to the patients who
- 3:58Speaker 1: participated and shared their stories. Their generosity and trust are
- 4:02Speaker 1: leading the way to precision treatments that could benefit so many.
- 4:06Speaker 2: Yes, and it's inspiring to see the research community moving
- 4:09Speaker 2: towards more personalized approaches. The results in this PHF study
- 4:14Speaker 2: are showing a strong pipeline for the future of clinical trials.
- 4:18Speaker 2: It's an exciting time for precision medicine in cardiology.
- 4:21Speaker 1: So, let's dive into the existing challenges of diagnosing and
- 4:24Speaker 1: treating HFPF. It's clear that the current clinical methods have
- 4:29Speaker 1: significant limitations. Thomas, can you explain some of the key issues?
- 4:34Speaker 2: Absolutely. One major issue is the variable nature of the condition. Rachel,
- 4:39Speaker 2: consider the complexity, even with all these risk factors like
- 4:43Speaker 2: aging and hypertension. The underlying mechanisms are still not fully understood.
- 4:48Speaker 2: Current clinical methods often fail to capture the subtle changes
- 4:52Speaker 2: happening in the heart and lungs.
- 4:54Speaker 1: Exactly. For example, it's challenging to differentiate between primary HFPF
- 4:59Speaker 1: and secondary consequences of other conditions like chronic obstructive pulmonary disease, COPD.
- 5:06Speaker 1: This variability makes early detection difficult and often leads to
- 5:10Speaker 1: delayed diagnosis.
- 5:11Speaker 2: Right. And when it comes to treatment, the current approaches
- 5:14Speaker 2: are mainly symptomatic. Drugs for pulmonary hypertension, like sildenafil, have
- 5:19Speaker 2: been explored but haven't shown significant improvement. This suggests that
- 5:24Speaker 2: a more tailored mechanistic approach might be needed.
- 5:27Speaker 1: That's a crucial point. The study by Raza and his
- 5:30Speaker 1: team at the University of Wisconsin-Madison and the Mortgage Institute
- 5:34Speaker 1: for Research is attempting to fill this gap. They are
- 5:38Speaker 1: using a multimodal approach to assess PHFPF exactly, and these
- 5:42Speaker 1: tests are allowing them to identify more detailed patterns. The
- 5:46Speaker 1: researchers found that RV dysfunction correlated with higher mortality and
- 5:50Speaker 1: hospitalization rates. This suggests that RV function is a better
- 5:55Speaker 1: prognostic indicator than what we currently use in clinical settings.
- 5:59Speaker 2: Exactly, bringing up an interesting contradiction. What we thought were
- 6:03Speaker 2: robust clinical methods might not be as reliable as we thought.
- 6:07Speaker 2: The study is using long, Read RNA sequencing to detect
- 6:11Speaker 2: gene expression variants. Finding genes like D3 are differentially expressed. Right.
- 6:16Speaker 1: This is where the molecular approach could potentially lead to
- 6:19Speaker 1: precision treatments. The team believes that focusing on specific cellular
- 6:24Speaker 1: mechanisms might yield breakthroughs. Raza envisions identifying subgroups of HFPF
- 6:30Speaker 1: patients and treating them with approved drugs that target specific mechanisms.
- 6:35Speaker 2: That's intriguing. The study's approach is really setting the stage
- 6:39Speaker 2: for precision medicine. It's exciting to see how these tools
- 6:43Speaker 2: might change the landscape of heart failure treatments in the
- 6:46Speaker 2: next few years.
- 6:47Speaker 1: Indeed. And it all comes down to the patients who
- 6:50Speaker 1: are willing to participate and share their stories. Their generosity
- 6:54Speaker 1: is truly leading the way towards more effective and personalized treatments. Wait,
- 7:00Speaker 1: but how does that actually play out in practice? How
- 7:03Speaker 1: do these findings translate into clinical practice? So, let's dive
- 7:08Speaker 1: into the molecular and cellular changes identified in the study.
- 7:12Speaker 1: It's fascinating to see how mitochondrial function plays a crucial
- 7:16Speaker 1: role in the condition.
- 7:17Speaker 2: Absolutely. The study uncovered that patients with right ventricular dysfunction, RVD,
- 7:23Speaker 2: show diminished mitochondrial function. Just imagine the energy powerhouse of
- 7:28Speaker 2: the cell, the mitochondria, might be working overtime, or just
- 7:32Speaker 2: not up to par, affecting the heart's ability to function properly.
- 7:36Speaker 1: That's a crucial nuance, and the research goes even deeper,
- 7:40Speaker 1: involving advanced RNA sequencing to detect gene expression variants. For instance,
- 7:47Speaker 1: the gene gate E3 showed differential expression in patients with
- 7:51Speaker 1: RV dysfunction compared to those without it.
- 7:53Speaker 2: Exactly, which brings up an interesting contradiction. Mitochondrial function is
- 7:59Speaker 2: vital for energy production, yet in HFPF, the same powerhouse
- 8:03Speaker 2: might be malfunctioning. leading to decreased energy production and consequently
- 8:09Speaker 2: increased right ventricular strain. It's like the heart's battery just
- 8:13Speaker 2: can't keep up with the demands.
- 8:14Speaker 1: Right. And this isn't just a theoretical finding. The study
- 8:19Speaker 1: used comprehensive cardiac assessments, invasive testing, and cardiac MRIs to
- 8:24Speaker 1: back up these observations. It's a multifaceted approach that's giving
- 8:28Speaker 1: us a clearer picture of what's going on beneath the surface.
- 8:32Speaker 2: True. And it's not just about the mitochondria. The study
- 8:36Speaker 2: also found elevated RNA metabolism and transport in these patients.
- 8:40Speaker 2: Imagine the machinery that handles genetic instructions is out of whack.
- 8:45Speaker 2: This could signal a cascade of cellular-level alterations that impact
- 8:49Speaker 2: how the heart functions, right? The study further differentiated between
- 8:53Speaker 2: patients with and without RVD, highlighting the importance of RV
- 8:57Speaker 2: function as a better prognostic indicator than current clinical methods.
- 9:01Speaker 2: It's like we are moving from a one-size-fits-all approach to
- 9:05Speaker 2: a more personalized, targeted treatment strategy.
- 9:07Speaker 1: Exactly. And this isn't just an academic exercise. The research
- 9:12Speaker 1: team is optimistic about its potential application in future clinical trials.
- 9:18Speaker 1: It's an exciting pipeline for precision medicine that could significantly
- 9:22Speaker 1: improve outcomes for patients with HFPF and RVD.
- 9:27Speaker 2: Definitely. And it's all thanks to the participants who shared
- 9:30Speaker 2: their stories and participated in the research. Their generosity is
- 9:35Speaker 2: truly leading the way towards more effective and personalized treatments,
- 9:39Speaker 2: just like you said earlier.
- 9:41Speaker 1: Indeed. Their commitment to the study is crucial. It's a
- 9:45Speaker 1: testament to the power of collaboration and the importance of
- 9:48Speaker 1: understanding the root causes of these conditions. With this knowledge,
- 9:53Speaker 1: we are one step closer to better treatments and improved
- 9:56Speaker 1: quality of life for those living with HFPF. So, the
- 10:00Speaker 1: findings are opening doors for precision medicine in treating HFPF.
- 10:04Speaker 1: But what does that really mean for patients? Let's break
- 10:07Speaker 1: it down. Precision medicine aims to tailor therapies based on
- 10:11Speaker 1: individual patient characteristics. What specific mechanisms are researchers looking to target?
- 10:16Speaker 2: Absolutely. For HFPF, researchers have identified some promising mechanisms. These
- 10:23Speaker 2: include mitochondrial dysfunction and increased RNA metabolism and transport. Take
- 10:29Speaker 2: the case of GATE3, a gene that's more active in
- 10:32Speaker 2: patients with right ventricular dysfunction, RVD. This could suggest a
- 10:37Speaker 2: role in energy metabolism, which is crucial for the heart's function.
- 10:41Speaker 1: That's fascinating. So if we can target these specific mechanisms,
- 10:46Speaker 1: would it lead to more effective treatments? For instance, could
- 10:49Speaker 1: we develop drugs that specifically address mitochondrial dysfunction?
- 10:53Speaker 2: Potentially, but it's not that simple. The study's findings are
- 10:57Speaker 2: a stepping stone. Right now, they have laid the groundwork
- 11:00Speaker 2: by identifying key pathways. For example, RVD patients with higher
- 11:05Speaker 2: mitochondrial function might have a better prognosis, indicating that maintaining
- 11:09Speaker 2: or enhancing this function could be beneficial.
- 11:11Speaker 1: It's almost like treating the heart differently based on its
- 11:14Speaker 1: own genetic blueprint. But what about the practical applications? How
- 11:19Speaker 1: do these findings translate into something tangible for patients?
- 11:23Speaker 2: Great question. Researchers are now focusing on comprehensive analysis to
- 11:28Speaker 2: refine their understanding. They believe that by categorizing patients based
- 11:33Speaker 2: on molecular patterns, treatments could become much more specific. For instance, levosomendon.
- 11:39Speaker 2: which initially failed in a clinical trial, might work if
- 11:43Speaker 2: given to a subset of patients whose hearts are struggling
- 11:46Speaker 2: due to specific imbalances.
- 11:47Speaker 1: And what about the potential for long-term benefits? Could this
- 11:51Speaker 1: research lead to a paradigm shift in how we approach HFPF?
- 11:56Speaker 2: Definitely. If successful, this could transform care by moving away
- 12:01Speaker 2: from a one-size-fits-all approach to something much more personalized. It's
- 12:05Speaker 2: a bit like the old saying, if everyone got the
- 12:07Speaker 2: same haircut, it might work for some, but it wouldn't
- 12:10Speaker 2: fit everyone.
- 12:11Speaker 1: That's a great analogy. And for those who might feel
- 12:14Speaker 1: overwhelmed by these complexities, it's reassuring to know that researchers
- 12:18Speaker 1: are working towards more precise and targeted therapies. It's really
- 12:22Speaker 1: about understanding the heart in a whole new way.
- 12:25Speaker 2: Exactly. And the most exciting part is that the more
- 12:28Speaker 2: we understand, the better we can care for patients. This
- 12:32Speaker 2: research is just the beginning. But it's laying the foundation
- 12:35Speaker 2: for a future where treatments aren't just effective, they are
- 12:39Speaker 2: tailored to the individual.
- 12:40Speaker 1: So, as we conclude this episode, let's take a moment
- 12:44Speaker 1: to lay out the future outlook for research in HFPF.
- 12:47Speaker 1: We know that precision medicine holds the key to unlocking
- 12:51Speaker 1: targeted treatments. But how do we get there?
- 12:54Speaker 2: Right, and that's where patient participation becomes so crucial. Without them,
- 12:59Speaker 2: We wouldn't have the rich data set necessary to differentiate
- 13:02Speaker 2: between subtypes of HFPF. Their involvement isn't just about data.
- 13:07Speaker 2: It's about ensuring treatments are as effective as possible.
- 13:10Speaker 1: Absolutely. Patients like those involved in the University of Wisconsin-Madison
- 13:15Speaker 1: and Mortgage Institute study are helping us identify key mechanisms.
- 13:19Speaker 1: For instance, they are showing us that RV dysfunction, which
- 13:23Speaker 1: often leads to better prognostic indicators, is a major player.
- 13:27Speaker 2: Exactly. And this brings up an interesting contradiction. The study
- 13:32Speaker 2: found that RV dysfunction correlates with higher hospitalization and mortality rates. Yet,
- 13:38Speaker 2: treatments like sildenafil, which were designed to increase blood flow,
- 13:42Speaker 2: led to increased turbulence and flooding in the lungs. This
- 13:46Speaker 2: reinforces the need for precisely tailored therapies that respect individual variability.
- 13:52Speaker 1: That's wild when you look at the raw numbers. The
- 13:55Speaker 1: precision has to be on point. And that's where ongoing
- 13:58Speaker 1: studies come in. The research team is analyzing heart tissue
- 14:02Speaker 1: from larger patient groups, which will undoubtedly reveal more about
- 14:06Speaker 1: the molecular and cellular variations within HFPF.
- 14:09Speaker 2: True, and it's vital for these studies to continue. The
- 14:13Speaker 2: team is planning to use long, read RNA sequencing to
- 14:17Speaker 2: detect gene expression variants. Some, like GAD3, show different expression
- 14:21Speaker 2: between patients with and without Wavy dysfunction. indicating a potential
- 14:26Speaker 2: role in energy metabolism and treatment targets.
- 14:30Speaker 1: So, the next step is to understand these differences and
- 14:33Speaker 1: translate them into practical treatments. Raza, the lead researcher, is
- 14:38Speaker 1: confident about the pipeline. He sees this as a multi-year
- 14:42Speaker 1: process where we will refine our approaches based on these findings.
- 14:46Speaker 2: Exactly. And Raza's gratitude towards the patients is a poignant
- 14:50Speaker 2: reminder of why this research is so important. Their generosity
- 14:55Speaker 2: and trust are paving the way for advancements that will
- 14:58Speaker 2: benefit not just them, but countless others in the future.
- 15:01Speaker 1: Indeed. It's about moving beyond the surface-level understanding and delving
- 15:06Speaker 1: into the complex, multifaceted nature of HFPAF. Each patient is unique.
- 15:14Speaker 1: And with precision medicine, we are getting closer to treatments
- 15:18Speaker 1: that can address the specific needs of individuals.
- 15:20Speaker 2: Right. And that means no more one-size-fits-all solutions. Instead, it's
- 15:25Speaker 2: about personalized care based on the latest research. The future
- 15:29Speaker 2: of HFPF treatment is looking much brighter if we can
- 15:32Speaker 2: just get there with the right tools and the support
- 15:34Speaker 2: of patients like those we have talked about today.
- 15:37Speaker 1: That brings us to the end of today's episode. Thank
- 15:40Speaker 1: you so much for spending part of your day with me.
- 15:42Speaker 1: If you found this episode's tips helpful and want to
- 15:45Speaker 1: make sure you don't miss the next conversation, please take
- 15:48Speaker 1: a quick second to hit that subscribe or follow button
- 15:51Speaker 1: on whatever platform you are listening on. It's a completely
- 15:54Speaker 1: free way to support the show and helps more people
- 15:57Speaker 1: find us. This podcast is independently produced, so if you
- 16:01Speaker 1: are ever in a position where you would like to
- 16:03Speaker 1: help keep it running, we do accept small donations. You
- 16:07Speaker 1: can find a link right in the episode description below
- 16:10Speaker 1: to buy us a coffee or contribute what you can.
- 16:13Speaker 1: Every bit genuinely helps. Take care of yourself, Stay balanced,
- 16:18Speaker 1: and we will talk again soon.